A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
NCT06241560
Idiopathic Pulmonary Fibrosis, Lung Diseases
The Woodlands, Texas, United States
View Trial DetailsNCT Number: NCT02407431
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
This study is active but is not currently recruiting participants.
18 year–100 year
All sexes
Observational
Johns Hopkins University, Baltimore, Maryland, United States
The primary objective is to create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network. Creating the IPF Clinician-Patient Partnership Cohort will involve:
The secondary objectives are to use the PaTH Network IPF Clinician-Patient Partnership Cohort to answer patient-centered research questions including:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 18 months
Create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network.
University of Pittsburgh
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06241560
Idiopathic Pulmonary Fibrosis, Lung Diseases
The Woodlands, Texas, United States
View Trial DetailsNCT05389215
Idiopathic Pulmonary Fibrosis, Lung Diseases
Mesa, Arizona, United States
View Trial DetailsNCT05241275
Idiopathic Pulmonary Fibrosis, Lung Diseases
Durham, North Carolina, United States
View Trial DetailsNCT06736990
Idiopathic Pulmonary Fibrosis, Lung Diseases
Los Angeles, California, United States
View Trial Details